TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and ...
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) is a clinical-stage biopharmaceutical company developing therapies and diagnostic-related tools aimed at combating and detecting metastatic disease. The company’s overarching goal is to contribute to a “cancer-free future” for patients by applying engineered molecular approaches to cancer immunology and gene regulation. It is headquartered in ...TransCode Therapeutics, Inc. (NASDAQ: RNAZ) is a clinical-stage biopharmaceutical company developing therapies and diagnostic-related tools aimed at combating and detecting metastatic disease. The company’s overarching goal is to contribute to a “cancer-free future” for patients by applying engineered molecular approaches to cancer immunology and gene regulation. It is headquartered in the Boston, Massachusetts area (with references to Newton, MA in company profile information) and focuses on oncology, particularly high-risk and advanced cancers.
Business-wise, TransCode’s strategy centers on an integrated pipeline of therapeutic candidates built around RNA and immune-stimulating mechanisms. A key element of its pipeline is TTX-MC138, identified as a lead compound undergoing preclinical evaluation for treating advanced, spreading cancers. In parallel, the company develops RNA interference (siRNA) programs such as TTX-siPDL1 (designed to modulate programmed death-ligand 1, PD-L1) and TTX-siLIN28B (aimed at inhibiting LIN28B), reflecting an approach that combines immune checkpoint biology and oncogenic pathway suppression.
Beyond its core lead candidate and siRNA efforts, TransCode also pursues additional cancer-agnostic initiatives. These include TTX-RIGA, an RNA-based agent designed to stimulate the RIG-I immune pathway in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9 gene-editing platform intended to correct or eliminate oncogenic genes within cancer cells; and TTX-mRNA, an mRNA platform intended to generate cancer vaccines capable of inducing cytotoxic immune responses against malignant cells. Together, these programs position the company as a multi-modality oncology platform company, with the common theme of RNA- and nucleic-acid-driven therapeutic design.
Cost and business operations information is limited in the provided materials; however, like many small clinical-stage biotechnology companies, TransCode appears to operate with constrained scale (reported full-time employees around 12) and likely prioritizes financing and runway extension to support ongoing preclinical and pipeline development. Consistent with this, company news references flexible financing arrangements intended to extend its operating runway into the late-2027/early-2028 timeframe.
From a leadership and governance perspective, Philippe Calais serves as CEO (and is also identified as Chief Executive Officer and Chairman of the Board in leadership materials). Overall, TransCode’s key “wishes” or objectives, as reflected in its public messaging, include advancing its oncology pipeline through development stages and ultimately improving outcomes for patients with metastatic and advanced cancers through intelligent, platform-driven therapeutic design.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-34.7M
-106.9%
+62.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-19.5M
-46.2%
+99.9%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.0%
+100.0%
—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
6.29x
+145.9%
-36.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
